QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Data Supplement All Versions of this Article: jpet.108.149955v1 330/1/304    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Google Scholar Articles by Zhu, F. Articles by Chen, Y. PubMed PubMed Citation Articles by Zhu, F. Articles by Chen, Y.

METABOLISM, TRANSPORT, AND PHARMACOGENOMICS

What Are Next Generation Innovative Therapeutic Targets? Clues from Genetic, Structural, Physicochemical, and Systems Profiles of Successful Targets

Bioinformatics and Drug Design Group, Center for Computational Science and Engineering, Departments of Pharmacy (F.Z., L.Y.H., C.J.Z., B.X., Y.Z.C.) and Biological Science (M.T.T.), National University of Singapore, Singapore; and State Key Laboratory of Biotherapy, Sichuan University, Chengdu, People's Republic of China (S.Y.Y., Y.Q.W., Y.Z.C.)

Low target discovery rate has been linked to inadequate consideration of multiple factors that collectively contribute to druggability. These factors include sequence, structural, physicochemical, and systems profiles. Methods individually exploring each of these profiles for target identification have been developed, but they have not been collectively used. We evaluated the collective capability of these methods in identifying promising targets from 1019 research targets based on the multiple profiles of up to 348 successful targets. The collective method combining at least three profiles identified 50, 25, 10, and 4% of the 30, 84, 41, and 864 phase III, II, I, and nonclinical trial targets as promising, including eight to nine targets of positive phase III results. This method dropped 89% of the 19 discontinued clinical trial targets and 97% of the 65 targets failed in high-throughput screening or knockout studies. Collective consideration of multiple profiles demonstrated promising potential in identifying innovative targets.

Address correspondence to: Prof. YuZong Chen, Department of Pharmacy, National University of Singapore, 18 Science Dr. 4, Singapore 117543. E-mail: phacyz{at}nus.edu.sg.